The enhancements in blood pressure and lipid profiles, in addition to their primary effects on glycemic control and body weight, augment the potential of GLP-1-RAs as comprehensive therapeutic choices for patients with T2DM, especially for those with multiple cardiovascular risk factors in their medical history [51,69]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.